Benign neutropenia, observed in different ethnic groups, is the most common form of neutropenia worldwide. A specific single nucleotide polymorphism, rs2814778, located at the promoter of the ACKR1 (previously termed DARC) gene, which disrupts a binding site for the GATA1 erythroid transcription factor, resulting in a ACKR1-null phenotype, was found to serve as a predictor of low white blood cell and neutrophil counts in African-Americans and Yemenite Jews. Individuals with benign neutropenia due to the ACKR1-null allele have been found to have an increased susceptibility to human immunodeficiency virus infection and, on the other hand, a protective effect against malaria. The associated protective effect may explain the spread of the ACKR1-null allele by natural selection. The reviewed relationships between ACKR1 polymorphism and various pathological states may have important clinical implications to individuals with and without benign neutropenia. Potential mechanisms for ACKR1 (previously termed DARC) modulation during neutrophil recruitment to inflammation, and chemokine bioavailability in the circulation and in local tissue are reviewed and discussed.
It has long been recognized that certain individuals from dark-skinned populations, who are otherwise healthy and do not suffer from repeated or severe infections, display low leucocyte and neutrophil counts (Haddy et al, 1999) . In studies focusing on African-Americans, researchers found that a low white blood cell (WBC) count was predominantly due to low neutrophil counts. This phenomenon has been called "benign ethnic neutropenia" as opposed to leucopenia (reviewed by Paz et al, 2011) . Benign neutropenia has been observed in different ethnic groups, including Africans, Americans, AfroCaribbeans, Jordanians, Israeli Bedouins, Ethiopian and Yemenite Jews (Weingarten et al, 1993; Paz et al, 2011) .
Benign ethnic neutropenia was first documented by Forbes et al (1941) who observed that neutrophil counts in healthy black sharecroppers in Mississippi were lower than those of white workers living under the same conditions. The observation that the mean neutrophil counts of black Americans are lower than those of white Americans was further confirmed (Broun et al, 1966; Orfanakis et al, 1970; Shaper & Lewis, 1971; Karayalcin et al, 1972) . Similar findings have been described in studies of Israeli Jews of Yemenite origin (Djaldetti et al, 1961) . In healthy individuals, neutrophils are the most abundant cell type amongst circulating WBCs and critical in providing antimicrobial activity against bacteria and fungi (Hsieh et al, 2007) . Individuals with low neutrophil counts, but not those with benign neutropenia, are at an increased risk of infection, especially from pyogenic and enteric bacteria, with fungal infections appearing when neutropenia is severe and prolonged (Pizzo, 1993) . The risk of infection is highest when the neutrophil count is <0Á5 9 10 9 /l for a prolonged period (Hsieh et al, 2007) . Neutropenia in adults and children >1 year of age was defined by Haddy et al (1999) as a reduction in circulating polymorphonuclear and band form neutrophils, with an absolute neutrophil count (ANC) <1Á5 9 10 9 /l. However, other definitions have been suggested, such as an ANC <2Á0 9 10 9 /l, proposed by Mason et al (1979) as applicable to the African-American population and by Weingarten et al (1993) vis-a-vis Yemenite Jews. Notably, recent studies have defined a lower limit of 2Á5 9 10 9 /l in benign neutropenia; below this level, there may be significant clinical implications (Ramsuran et al, 2011) .
The Duffy Antigen (ACKR1, previously termed DARC)
capillaries and post-capillary venular endothelial cells (Lee et al, 2003a) , functioning as a chemokine receptor and a receptor for the malarial parasite Plasmodium vivax (Miller et al, 1976; Horuk et al, 1993) . The gene encoding the ACKR1 human blood group (ACKR1, previously termed DARC) is localized on chromosome 1q22-23 (Tournamille et al, 1995a; Howes et al, 2011) . There are two common alleles in Caucasians; FY*A and FY*B, coding the FYa and FYb antigens, respectively (Tournamille et al, 1995a) . These alleles differ by a single base substitution in the second position of codon 42 (G125A), resulting in two different encoded proteins, differentiated by a single amino acid, a glycine residue in FYa and an aspartic acid residue in FYb (Gly42Asp) (Chaudhuri et al, 1995; Howes et al, 2011) . The two different alleles can result in three possible genotypes: FY*A/ FY*B, FY*A/FY*A and FY*B/FY*B, encoding three phenotypes, respectively: Fy(a+bÀ), Fy(aÀb+) and Fy(a+b+). A fourth null phenotype of ACKR1, Fy(aÀbÀ) has been described (Tournamille et al, 1995a,b) . Individuals harbouring this phenotype are designated 'Duffy negative individuals', 'ACKR1-null phenotype', 'ACKR1-null allele (FYÀ)', 'Fy null-allele' or 'the null 'erythrocyte silent' (ES) phenotype (Tournamille et al, 1995a; Howes et al, 2011) . This phenotype is rare in Caucasians but represents the major allele in blacks (Tournamille et al, 1995a) . Howes et al (2011) generated global frequency maps of the common Duffy alleles and found that the most common allele worldwide is FY*A, while in sub-Saharan Africa, the prevalent allele phenotype is the silent Fy(aÀbÀ) variant.
ACKR1 polymorphism and the null phenotype
Nucleotide sequence analysis of the open reading frame from the ACKR1-null allele patients failed to show evidence of a mutation in the coding sequence of the gene (Chaudhuri et al, 1995) . ACKR1 is a short, single exon gene (1549 bp) similar to several genes encoding G-protein-coupled receptors. Analysis of ACKR1 gene promoter revealed two putative binding sequences for the GATA transcription factor family (Tournamille et al, 1995b ) and a polymorphic change was identified in one of the putative GATA binding sites. A single T to C substitution, upstream of the gene transcription initiation site, at nucleotide À46 (Tournamille et al, 1995b; Nalls et al, 2008; Reich et al, 2009 ) was found and designated rs2814778. Duffy-negative individuals Fy(aÀbÀ) are homozygous for this polymorphism (C/C), resulting in the lack of a ACKR1 expression on erythrocytes (FYÀ), whereas the heterozygous state (T/C) and the wild type state (T/T) enable the expression of the Duffy molecule in RBCs (FY+) (Tournamille et al, 1995b; Nalls et al, 2008; Reich et al, 2009 ). The C/C genotype was shown to impair the promoter activity of ACKR1 in erythroid cells by disrupting the binding site of the GATA1 erythroid transcription factor (Tournamille et al, 1995b) . Reich et al (2009) reported that homozygous individuals (C/C) for the null allele exhibit distinctly lower neutrophil counts compared to carriers of the functional allele. Furthermore, it was demonstrated that the rs2814778 single nucleotide polymorphism (SNP) associates more strongly with the neutrophil count than with ancestry (Reich et al, 2009) , suggesting that this SNP could initiate the phenomenon of benign neutropenia not only in African-Americans. The mean neutrophil count among homozygous individuals (C/C) was reported to be~2Á5 9 10 9 /l, while the mean neutrophil count among heterozygous (T/C) or wild type (T/T) individuals was~4Á0 9 10 9 /l (Reich et al, 2009 ). Others confirmed that Duffy-negative healthy patients have lower WBC and neutrophil counts (Drasar et al, 2013) . We recently demonstrated a correlation between C/C homozygosity of this SNP and benign neutropenia in Yemenite Jews, with a mean neutrophil count of 1Á75 9 10 9 /l among homozygous individuals and a 46-fold higher risk for neutropenia than C/T heterozygotes at this polymorphic site (Rappoport et al, 2015) . It should be noted that there have been reports of neutropenic individuals without the typical ACKR1 SNP (Reiner et al, 2011) , indicating that some familial neutropenias might be due to other mutations that cause low ANC (Palmblad & Hoglund, 2018) . In addition, the Fy(aÀbÀ) phenotype was found to be overwhelmingly prevalent in neutropenic African Americans, but was also found in one-third of individuals with normal/high ANC, suggesting additional ANC influences from other genetic traits (Charles et al, 2018; Palmblad & Hoglund, 2018) .
In the last few years, special attention was paid to the population of children with sickle cell anaemia. Candidate genetic polymorphisms were studied in sickle cell anaemia paediatric cohorts by performing whole exome sequencing. Among candidate genes, the ACKR1 rs2814778 polymorphism, regulating Duffy antigen expression, had a clear influence with significantly increased WBC and neutrophil counts, however, it did not affect the maximum tolerated dose of hydroxycarbamide therapy (Schaefer et al, 2016) .
The ACKR1 protein ACKR1 is a multispecific chemokine receptor with a promiscuous binding profile for both the CXC and CC classes of chemokines (Tournamille et al, 1995a; Gardner et al, 2004) . It selectively binds with high affinity pro-inflammatory and angiogenic chemokines, such as interleukin 8 (CXCL8), RANTES (CCL5), monocyte chemotactic protein-1 (MCP1, CCL2) and melanoma growth-stimulating activity, alpha (MGSA, CXCL1), but not homeostatic chemokines or angiostatic ELR À chemokines (Szabo et al, 1995; Gardner et al, 2004; Bonecchi et al, 2008) . Thus, ACKR1 affects the inflammatory response by neutrophil recruitment and migration. ACKR1 is a 338-amino-acid glycosylated protein, organized into seven trans-membrane domains (Tournamille et al, 1995b) . Its four extracellular domains interact with chemokines, and the N-terminal extracellular region is essential in binding the Plasmodium vivax merozoites (Chitnis et al, 1996; Tournamille et al, 2003; Choe et al, 2005) . However, unlike other chemokine receptors with a seven-transmembrane receptor structure and a signalling function, ACKR1 lacks a G-protein binding motif, therefore, it does not directly participate in signal transduction or cell migration (Chakera et al, 2008) . Nonetheless, ACKR1 is capable of internalizing bound chemokines (Peiper et al, 1995) , as CCR5 binding to ACKR1 leads to heterodimerization and inhibition of CCR5 signalling (Chakera et al, 2008; Schnabel et al, 2010) . Therefore, it has been proposed that ACKR1 belongs to a subfamily of "silent" chemokine receptors and acts as a decoy and scavenger for chemotactic agonists (Bonecchi et al, 2008) . It has been argued that ACKR1 is unique as a chemokine receptor in that internalized chemokines remain fully active (Schnabel et al, 2010) .
As mentioned, ACKR1 is not solely expressed in erythroid cells. Venular endothelial expression of ACKR1 in both Duffy-negative and Duffy-positive individuals has been found in various normal tissues, including splenic and bone marrow (BM) sinusoids (Chaudhuri et al, 1993; Peiper et al, 1995) . ACKR1 is also expressed in Purkinje cells in the cerebellum and in adjacent regions of the brain stem . ACKR1 is highly conserved across mammalian species (Hadley & Peiper, 1997) .
Possible mechanisms underlying benign neutropenia
During the past 30 years, several hypotheses regarding the cause of benign neutropenia have been proposed. To investigate the mechanism underlying benign neutropenia, the response to different stimuli was examined. African American smokers were found to exhibit lower neutrophil counts compared to Caucasian smokers (Hsieh et al, 2007) . The ANC in benign ethnic neutropenia may also vary because of age (Ortiz et al, 2016) and minor infections (Palmblad & Hoglund, 2018) . Mason et al (1979) showed that the mean neutrophil increment after hydrocortisone administration to black control subjects was significantly lower than in white control subjects, and Phillips et al (2000) demonstrated a reduced ability of African/Afro-Caribbeans to mobilize neutrophils from the marginal granulocyte pool compared to healthy white subjects, in response to exercise. However, other studies demonstrated that individuals with benign neutropenia responded aberrantly to steroids and lithium (Schneider et al, 1982; Shoenfeld et al, 1982) . Mayr et al (2008) found that the peak plasma neutrophil counts were similar in both Duffy-negative and Duffy-positive subjects in response to lipopolysaccharide (LPS) stimulation, although Duffy-negative subjects had significantly lower baseline neutrophil and monocyte counts. Recently, a significant increase in neutrophil count performed in the afternoon compared to the neutrophil count performed in the morning among individuals with benign ethnic neutropenia was shown. This was hypothesized to be due to expected higher granulocyte colony-stimulating factor (G-CSF) basal levels and a greater physiological response to this cytokine among individuals with benign ethnic neutropenia. This phenomenon could support the diagnosis of benign ethnic neutropenia, hence prevent unnecessary further assessment of these individuals, reducing costs of laboratory tests and patient concerns (Souto Filho et al, 2018) . Weingarten et al (1993) suggested a defect in the release of mature granulocytes from the marrow into the marginal pool. Several studies have examined the BM cells of patients with benign neutropenia. Normal morphology and maturation of all cell lineages without an increase in young cells of the granulocyte series in the peripheral blood (Mintz & Sachs, 1973) or changes in other leucocyte counts were reported (Dancey & Brubaker, 1980; Shoenfeld et al, 1985) . These findings indicate that benign neutropenia is not associated with a stem cell defect or myeloid maturation (Hsieh et al, 2010) . However, the possibility that individuals of African ancestry have both increased margination and an impaired ability to mobilize neutrophils was not excluded, but appeared unlikely (Phillips et al, 2000) . It has also been suggested that the ACKR1 protein affects blood counts of circulating neutrophils by modulating the concentrations of chemokines in vascular beds in the BM (Bonecchi et al, 2008) .
A novel fundamental role for ACKR1 in haematopoiesis was presented by Duchene et al (2017) , whereby the absence of erythroid ACKR1 altered mouse haematopoiesis, including stem and progenitor cells, which ultimately led to phenotypically distinct neutrophils that readily left the circulation. Individuals with a Duffy-negative phenotype developed a distinct profile of neutrophil effector molecules that closely reflected the one observed in the Ackr1-deficient mice. These characteristics include overexpression of Fcc-receptors (FccR; CD16/32), key molecules involved in neutrophil antimicrobial defences, and CD45, a molecule that amplifies FccR function, also FccRIIIb (CD16) and CCR2. These changes were required, but not sufficient alone, to cause neutropenia, and neutropenia only occurred when the Daffy antigen was expressed on venular endothelial cells, as in Duffy-negative individuals, possibly by facilitating these altered neutrophils exit into the tissues. Moreover, according to the study, neutrophils that developed in ACKR1-deficient BM preferentially homed into spleens of the wild-type parabionts, but not other organs tested, which included BM, liver and lungs. It is not clear if altered neutrophils that migrate into spleen persist there or may be part of their clearance from circulation (Duchene et al, 2017) .
Furthermore, a very recent study confirmed that rs2814778 in ACKR1 was associated with benign ethnic neutropenia (Charles et al, 2018) . Using whole genome expression profiling, the study suggested that neutrophils in benign ethnic neutropenia individuals functioned similarly to neutrophils from non-benign ethnic neutropenia individuals, while showing that benign ethnic neutropenia neutrophils had slightly activated profiles in leucocyte migration and haematopoietic stem cell mobilization pathways (Charles et al, 2018) .
These findings support the hypothesis that the relative neutropenia in benign ethnic neutropenia individuals results from ACKR1-null progenitors preferentially differentiating to myeloid cells, leading to activated neutrophils migrating from the blood circulation to the tissues, particularly the spleen (Duchene et al, 2017; Charles et al, 2018; Palmblad & Hoglund, 2018) . In order to determine whether this hypothesis explains benign ethnic neutropenia partly or completely, or to determine whether benign ethnic neutropenia is a true neutropenic state, the total number of neutrophils in the body (TBNC) needs to be evaluated, which is still lacking (Palmblad & Hoglund, 2018) .
ACKR1 in inflammation
A critical biological function of ACKR1 in inflammation has been proposed due to its role as a binding receptor to chemo-attractant cytokines on endothelial cells in Duffynegative individuals who lack the erythrocyte Duffy antigen (Lee et al, 2003a) . Interestingly, ACKR1 was found to be upregulated during various inflammatory conditions (Segerer et al, 2000; Lee et al, 2003b; Pruenster & Rot, 2006) , and endothelial cells of larger vessels were shown to react with ACKR1 antibodies under inflammatory conditions (i.e., temporal arteritis, thrombophlebitis, omphalitis) (Hadley & Peiper, 1997) . These findings suggest that ACKR1 expression is controlled by tight tissue-specific regulation (Tournamille et al, 1995b) .
Despite the substantial progress in studying the roles of ACKR1 in inflammation, there are conflicting and discrepant findings, postulating three different models ( Fig. 1): 1. ACKR1 lacks a G-protein-coupling motif (Chaudhuri et al, 1993) and so it does not directly participate in signal transduction. It has been suggested that ACKR1 influences plasma levels of pro-inflammatory chemokines by acting as a negative regulator or a "chemokine sink/depot" (Darbonne et al, 1991; Dawson et al, 2000; Rot, 2005; Lee et al, 2006; Pruenster & Rot, 2006; Bonecchi et al, 2008) (Fig. 1A) . According to this model, erythrocyte ACKR1 binds plasma chemokines, thereby preventing chemokine loss from the circulation, on one hand, and the activation of leucocytes on the other hand (Rot, 2005) , raising the possibility of a protective effect of erythrocyte-associated ACKR1. Indeed, Lee et al (2006) found significantly higher plasma concentrations of CXCL8/IL8 and CCL2/MCP1 in homozygous carriers than heterozygosity for the polymorphism following LPS stimulation. Similarly, they showed in Dfy(À/À) mice higher plasma MIP2 concentrations than Dfy(+/+) mice following LPS stimulation of whole blood, demonstrating that erythrocyte Duffy antigen reduces soluble chemokine concentrations in the blood compartment during an inflammatory state in vitro (Lee et al, 2006) . Earlier, in the same mouse model Dawson et al (2000) found a more severe lung inflammation compared with Ackr1 wild type mice, following an intraperitoneal injection of LPS (Dawson et al, 2000) . Nonetheless, analysis of inflammatory cytokines in a recent study, showed similar levels in individuals homozygous for the rs2814778 C allele compared to others, indicating that the cytokine sink hypothesis played a minor role in leucocyte/neutrophil homeostasis (Charles et al, 2018) . 2. In contrast to the hypothesis that ACKR1 reduces intensity of inflammation, some have postulated that endothelial Duffy antigen could play a pro-inflammatory role via regulation of chemokine concentration and influence on neutrophil migration. Based on cumulative experimental evidence, several studies have hypothesized that endothelial ACKR1 may facilitate the transfer (transcytosis) of chemokines across endothelial cells, thereby affecting leucocyte recruitment to inflammation sites (Rot et al, 1996; Middleton et al, 1997; Lee et al, 2003b; Rot, 2005) (Fig. 1B) . In the inflamed tissue, endothelial Duffy antigen binds chemokines and promotes selective chemokine mobilization via their internalization and mobilization from the abluminal surface to the luminal surface, resulting in reduced local chemokine concentrations. Chemokines are then presented to circulating cells by heparan sulfate proteoglycans on the luminal surface of the endothelium (Rot et al, 1996; Middleton et al, 1997 Middleton et al, , 2002 Lee et al, 2006) . 3. Recent studies have proposed a third model whereby ACKR1 can serve as a chemokine reservoir, maintaining soluble chemokine levels in the blood and local tissue compartments, thus regulating inflammation (Fukuma et al, 2003; Lee et al, 2006; Mayr et al, 2008) . By employing the 'reservoir model' (Fig. 1C) , when erythrocytes continuously traverse local tissue vascular beds, the erythrocyte ACKR1 binds chemokines when concentrations are elevated during tissue inflammation and systematically discharges them into the circulation when the plasma chemokine concentrations decrease below the K d value. Therefore, ACKR1 improves systemic bioavailability of chemokines generated during local tissue inflammation, thus affecting neutrophil recruitment to these tissues (Lee et al, 2006) .
A unifying hypothesis to the three suggested models describing the function of ACKR1 as a regulator of inflammation would be, that ACKR1 might act as a sink for chemokines in the local inflamed tissue while acting as a reservoir for chemokines in the plasma (Fukuma et al, 2003) , and that it may be capable of transducing chemokines across endothelial cells, which would lead to their presentation to circulating leucocytes. The versatile functions of ACKR1 may indicate its A study examining whether ethnic benign neutropenia among Yemenite Jews reduces chronic low-grade inflammation (prevalent among apparently healthy subjects) demonstrated that despite reduced WBC counts, they exhibited enhanced concentrations of inflammatory biomarkers such as fibrinogen, and a significantly enhanced C-reactive protein concentration, compared to the reference group. These results indicate that ethnic neutropenia is probably not an expression of an absent or lesser degree of chronic low-grade inflammation. However, no significant differences were noted regarding the inflammatory biomarkers between leucopenic (WBC count <5Á0 9 10 9 /l) and non-leucopenic Yemenite
Jews (Berliner et al, 2005) . Higher IL8 and G-CSF levels in African rather than Caucasian volunteers were documented by Mayr et al (2007) , but that was not confirmed in a recent study (Charles et al, 2018) . When investigating the role of ACKR1 and specific chemokines in rheumatoid arthritis, it was found that the expression of ACKR1 and CXCL5 on endothelial cells is essential for the recruitment of neutrophils to the inflamed synovium in this autoimmune disease (Smith et al, 2008) . Furthermore, it has been suggested that neutrophil counts correlate with the risk of vaso-occlusion and, consequently, diseases such as leg ulceration and renal dysfunction (Drasar et al, 2013) . Accordingly, benign neutropenia among Yemenite Jews has been suggested as producing a protective effect against atherosclerotic disease (Ernst et al, 1987) . In addition, ACKR1was found to have a role in asthma pathophysiology both in a mouse model and in a group of poorly controlled asthmatics, in which ACKR1 SNPs were associated with worse asthma control (Chapman et al, 2017) . The ACKR1 genotype was not found to be significantly associated with Behc ßet disease (Pittoni et al, 2003) . Considering the important role of ACKR1 in inflammation, the absence of ACKR1 may indicate a subtle dysfunction of the inflammatory response rather than a protective effect, a hypothesis to be further investigated.
ACKR1 polymorphism and susceptibility to infections
Benign neutropenia in dark skinned populations does not seem to predispose to regular bacterial infections (Shoenfeld et al, 1985) and is not associated with altered outcomes after a bacterial infection. A recent study focusing on the clinical characteristics of a paediatric cohort with benign ethnic neutropenia found a clinical course comparable to other healthy children, including otherwise normal blood counts, except for mild anaemia, although the median neutrophil count of children with benign ethnic neutropenia in this study was lower than previous reports in adults (Ortiz et al, 2016) .
Studies have suggested that the ACKR1 polymorphism may be relevant to susceptibility in other types of infections. For example, ACKR1 was found to serve as a receptor for the S. aureus haemolytic leucocidins, LukED and HlgAB. ACKR1 is required for S. aureus-mediated lysis of human erythrocytes, and ACKR1 overexpression renders cells susceptible to toxin-mediated lysis (Spaan et al, 2015) .
No increase of infection was noted also in individuals with ethnic neutropenia who develop a clozapine-induced decrease of the neutrophil count (Manu et al, 2016) , leading to a change in the US Food and Drug Administration (FDA) guidelines, allowing those with benign ethnic neutropenia the opportunity to be commenced on clozapine (Sultan et al, 2017) . A similar approach was adopted for deferiprone (Tricta et al, 2016) , which may be relevant to other druginduced neutropenias as well (Palmblad & Hoglund, 2018) .
The ACKR1-null allele is associated with reduced susceptibility to malaria infections caused by P. vivax (Hamblin & Di Rienzo, 2000) or P. falciparum (McMorran et al, 2012) . The Duffy antigen is utilized by the malarial parasite P. vivax, which enters the RBC (Hadley & Peiper, 1997; Rot, 2005) . Accordingly, the homozygous C/C state is considered resistant to P. vivax infection (Lee et al, 2003a) . In the case of P. falciparum, the underlying mechanism determines an association between the ACKR1 and this parasite, resulting in an internalization of the complex into the cell. Consequently, a protective role for platelets against malaria infection was suggested (Hadley & Peiper, 1997; McMorran et al, 2012 McMorran et al, , 2013 . The associated protective effects may explain the spread of the ACKR1-null FYÀ (C/C) polymorphism by natural selection in geographical areas of malaria transmission, such as Western, Central and South-Eastern Africa, with prevalence reaching almost 100% (Hamblin & Di Rienzo, 2000) . Given that the rates of infection and death due to P. falciparum are nevertheless high in Africa, relative to the rest of the world (Hay et al, 2009) , it was hypothesized that positive selection for the ACKR1-null polymorphism occurred when a lethal form of P. vivax prevailed, prior to emergence of P. falciparum as a human pathogen (McMorran et al, 2012 (McMorran et al, , 2013 . As ACKR1 negativity plays as a protective factor in P. vivax infection, inhibitors of ACKR1 will probably be effective in preventing P. vivax malaria. This mechanism is similar to inhibition of CCR5, the co-receptor for human immunodeficiency virus (HIV), preventing HIV infection (Ntumngia et al, 2016) .
The ACKR1-null FYÀ allele and benign neutropenia have also been associated with an increased risk of HIV infection and an altered disease progression, even though conflicting evidence exists (Walley et al, 2009 . A recent study in high-risk South African black women found that the ACKR1-null allele and an associated neutrophil count <2Á5 9 10 9 /l correlated with a~3-fold greater risk of acquiring an HIV infection. In this cohort, only FYÀ (C/C) homozygous subjects had pre-seroconversion neutrophil counts of 2Á5 9 10 9 /l (Ramsuran et al, 2011) . Similarly, an independent study found a 40% higher rate of acquiring HIV-1 infection among individuals with the ACKR1-null allele (He et al, 2008) . FYÀ individuals also exhibited a significantly slower rate of disease progression compared to carriers of the FY+ allele. Intriguingly, only leucopenic but not non leucopenic HIV positive FYÀ African-Americans had a survival advantage compared to FY+ individuals ). This advantage was more noticeable in subjects with lower WBC counts. Therefore, a more prolonged infectious state may exist among the FYÀ individuals, resulting in an increased risk of transmission and infection, which may contribute to the HIV epidemic in Africa (Ramsuran et al, 2011) . Interestingly, similarly to malaria, there is a geographical overlap between the prevalence of the ACKR1-null allele and HIV infection in Africa (Ramsuran et al, 2011) . The mechanism is currently unknown, but it is presumed that low neutrophil counts or altered chemokine concentrations play a role in the observed modulation of infection in FYÀ carriers (He et al, 2008) . Regarding the slower disease progression, He et al (2008) asserted that attachment between HIV-1 and the erythrocyte via the ACKR1 molecule may be impaired in FYÀ individuals. This is due to the observation that ACKR1 is a binding protein for chemokines affecting HIV cell entry, and that HIV-1 absorbs to erythrocyte ACKR1, suggesting that RBCs might act as carriers of HIV particles to target cells (Ramsuran et al, 2011) .
ACKR1 polymorphism and risk for sepsis
The relationships between benign neutropenia, ACKR1 phenotype, sepsis risk and outcome are still ambiguous. Studies have been published relating to racial differences in frequency and outcome of sepsis, with a doubling of the probability for sepsis among black subjects (Angus & Wax, 2001; Martin et al, 2003) . People of African descent examined in gene polymorphism studies were found to be associated with a high expression profile of pro-inflammatory and a low expression profile of anti-inflammatory cytokines compared to Caucasians (Cox et al, 2001; Hoffmann et al, 2002; Ness et al, 2004) . Reid et al (2002) observed that an unbalanced profile between pro-inflammatory and anti-inflammatory cytokines was linked to poorer survival in septic patients. Bozza et al (2007) noted that chemokines, especially MCP1 and IL8, correlate with sepsis severity. However, Zisman et al (1997) found that increased MCP1 plasma levels were associated with better survival in murine sepsis. This finding is especially interesting considering that significantly lower MCP1 levels were found in Duffy-negative subjects compared to Duffy-positive subjects (Mayr et al, 2008) . However, a cytokine profile analysis in septic patients contradicts the theory that a protective effect is associated with high MCP1 levels. MCP1 actually rose in severe sepsis and accurately predicted mortality (Bozza et al, 2007) . Consequently, the ACKR1-null allele could potentially affect critically ill patients with sepsis (Reich et al, 2009 ).
Possible implications of benign neutropenia in cancer
A possible relationship between benign neutropenia and cancer has also been suggested. Several studies have shown that African-Americans have lower pre-and post-chemotherapy leucocyte and neutrophil counts compared with white subjects (Hershman et al, 2005; Smith et al, 2005) . A lack of awareness to the cause of these low blood counts in AfricanAmerican women may explain the recurrent dose modification, treatment delays, less intensive therapy for early stage breast cancer and higher cancer-related mortality (Hershman et al, 2003 (Hershman et al, , 2005 Smith et al, 2005) . Further corroboration of this premise has shown that the nadir neutrophil counts and incidence of febrile neutropenia after a first cycle of chemotherapy seem more comparable between white and African-American patients with early-stage breast cancer and, notably, serve as better predictors for resulting treatment delays than pre-treatment leucocyte or neutrophil counts (Silber et al, 1998; Smith et al, 2005) . Variations in ACKR1, GSDMA and CXCL2 genes were found to play a role in the onset of chemotherapy complications, as was recently demonstrated in children with acute lymphoblastic leukaemia. ACKR1 polymorphism rs3027012 at the 5 0 -UTR was associated with higher risk of low absolute phagocyte count and hospitalization due to febrile neutropenia, while protective effect was instead seen for ACKR1 rs12075 A to G substitution (Glisovic et al, 2018) . There are indications that ACKR1-mediated chemokine sequestration assists in determining tumour microenvironment, angiogenesis and metastasis (Bandyopadhyay et al, 2006; Shen et al, 2006) . It has been demonstrated that ACKR1 ligates the tetraspanin CD82 on tumour cells, triggering tumour cell senescence and suppressing metastasis (Bandyopadhyay et al, 2006; Iiizumi et al, 2007) . Wang et al (2006) confirmed that the low expression of ACKR1 in human breast cancer relates to oestrogen receptor status, microvessel density, lymph node, peripheral metastasis and poor survival. Du et al (2002) demonstrated an anti-angiogenic effect of endothelial ACKR1 as transgenic mice overexpressing ACKR1 on vascular endothelium showed a lower angiogenic response to CXCL3 in corneal micropocket assay. Other authors also found a decreased growth rate of melanoma tumour xenografts and intratumoural blood vessels (Horton et al, 2007) . Two diverse ACKR1-transfected tumour cell lines showed decreased tumour-associated vasculature and reduction in metastatic potential (Addison et al, 2004; Wang et al, 2006) . It was suggested that neutropenia in African-Americans can predict a high tumour grade at prostatectomy (Sadeghi et al, 2012) . In concurrence, a model of prostate cancer demonstrated that the absence of ACKR1 expression was linked to increased intratumoural concentrations of the ACKR1 ligands, angiogenic chemokines CXCL1 and CXCL3, thus resulting in greater tumour growth mortality . The authors implied an association between a ACKR1-negative phenotype in humans, a 60% greater incidence of prostate cancer and increased mortality . After studying Ackr1À/À mice, the authors suggested that erythrocyte DARC clears angiogenic CXC chemokines from the prostate tumour circulation, thereby acting as an anti-angiogenic factor.
Conclusions
The relationships between the ACKR1 polymorphism and various pathological states may have important clinical implications for benign neutropenia in Duffy-negative individuals, as well as for the entire health care system. It is possible, for example, that reduced neutrophil counts in various pathological states, such as infectious, autoimmune and cancer diseases, may alter the therapy course, perhaps unnecessarily in patients with benign neutropenia, leading to a worse outcome. Thus, ongoing research of the clinical expression and outcome of patients harbouring the different ACKR1 genotypes in these conditions is critically important.
